In this episode of Investor Connect, we welcome Ken from Synaptically, who introduces a groundbreaking personalized therapy for Alzheimer’s disease. He discusses their innovative use of Transcranial Magnetic Stimulation (TMS) paired with Electroencephalograms (EEG) to achieve unprecedented results in slowing down disease progression.

With two successful phase two clinical trials and strong validation from scientific experts, the therapy shows significant improvements in cognition, function, and behavior in patients. Ken explains how their technology targets neuroplasticity, creating new brain connections and preserving brain microstructure and gray matter volume, with minimal side effects.

The discussion also touches on Synaptically’s strong financials, market strategy, and future prospects, including potential FDA approval and investment opportunities for interested parties.

 

Thank you for joining us for the Startup Funding Espresso where we help startups and investors connect for funding.

Let’s go startup something today.

_______________________________________________________

For more episodes from Investor Connect, please visit the site at: http://investorconnect.org 

Check out our other podcasts here: https://investorconnect.org/ 
For Investors check out: https://tencapital.group/investor-landing/ 
For Startups check out: https://tencapital.group/company-landing/ 
For eGuides check out: https://tencapital.group/education/ 
For upcoming Events, check out https://tencapital.group/events/  

For Feedback please contact info@tencapital.group   

Please follow, share, and leave a review.

Music courtesy of Bensound.

Copyright (c) 2025, Hall Martin and investorconnect.org. All rights reserved.

Disclaimer:
Hall T Martin is the director of Investor Connect, which is a 501(c)(3) nonprofit dedicated to the education of investors for early-stage funding. All opinions expressed by Hall and podcast guests are solely their own opinions and do not reflect the opinion of Investor Connect. This podcast is for informational purposes only and should not be relied upon for the basis of investment decisions.